AU2017278931B2 - Improved methods for detecting and modulating the embryonic-fetal transition in mammalian species - Google Patents

Improved methods for detecting and modulating the embryonic-fetal transition in mammalian species Download PDF

Info

Publication number
AU2017278931B2
AU2017278931B2 AU2017278931A AU2017278931A AU2017278931B2 AU 2017278931 B2 AU2017278931 B2 AU 2017278931B2 AU 2017278931 A AU2017278931 A AU 2017278931A AU 2017278931 A AU2017278931 A AU 2017278931A AU 2017278931 B2 AU2017278931 B2 AU 2017278931B2
Authority
AU
Australia
Prior art keywords
cells
itr
tissue
embryonic
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017278931A
Other languages
English (en)
Other versions
AU2017278931A1 (en
Inventor
Dana Larocca
Michael D. West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serina Therapeutics Inc
Original Assignee
Agex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agex Therapeutics Inc filed Critical Agex Therapeutics Inc
Publication of AU2017278931A1 publication Critical patent/AU2017278931A1/en
Assigned to AGEX THERAPEUTICS, INC. reassignment AGEX THERAPEUTICS, INC. Request for Assignment Assignors: BIOTIME, INC.
Priority to AU2023203808A priority Critical patent/AU2023203808A1/en
Application granted granted Critical
Publication of AU2017278931B2 publication Critical patent/AU2017278931B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2017278931A 2016-06-07 2017-06-07 Improved methods for detecting and modulating the embryonic-fetal transition in mammalian species Active AU2017278931B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023203808A AU2023203808A1 (en) 2016-06-07 2023-06-16 Improved methods for detecting and modulating the embryonic-fetal transition in mammalian species

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662347075P 2016-06-07 2016-06-07
US62/347,075 2016-06-07
US201762442219P 2017-01-04 2017-01-04
US62/442,219 2017-01-04
PCT/US2017/036452 WO2017214342A1 (en) 2016-06-07 2017-06-07 Improved methods for detecting and modulating the embryonic-fetal transition in mammalian species

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023203808A Division AU2023203808A1 (en) 2016-06-07 2023-06-16 Improved methods for detecting and modulating the embryonic-fetal transition in mammalian species

Publications (2)

Publication Number Publication Date
AU2017278931A1 AU2017278931A1 (en) 2018-12-20
AU2017278931B2 true AU2017278931B2 (en) 2023-06-29

Family

ID=60578097

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017278931A Active AU2017278931B2 (en) 2016-06-07 2017-06-07 Improved methods for detecting and modulating the embryonic-fetal transition in mammalian species
AU2023203808A Pending AU2023203808A1 (en) 2016-06-07 2023-06-16 Improved methods for detecting and modulating the embryonic-fetal transition in mammalian species

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023203808A Pending AU2023203808A1 (en) 2016-06-07 2023-06-16 Improved methods for detecting and modulating the embryonic-fetal transition in mammalian species

Country Status (6)

Country Link
US (4) US20190175691A1 (https=)
EP (1) EP3463391A4 (https=)
JP (2) JP2019517538A (https=)
AU (2) AU2017278931B2 (https=)
CA (1) CA3026874A1 (https=)
WO (1) WO2017214342A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3888640B1 (en) 2013-06-05 2025-09-17 Reverse Bioengineering, Inc. Compositions and methods for induced tissue regeneration in mammalian species
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
CN108779435B (zh) 2015-12-07 2022-05-03 再生疗法有限公司 用于重新衍生不同的多能干细胞衍生的褐色脂肪细胞的方法
AU2017278931B2 (en) * 2016-06-07 2023-06-29 Agex Therapeutics, Inc. Improved methods for detecting and modulating the embryonic-fetal transition in mammalian species
CN108665091A (zh) * 2018-04-07 2018-10-16 深圳供电局有限公司 一种基于机器学习的物资智能调度方法
US20210180013A1 (en) * 2018-04-23 2021-06-17 Agex Therapeutics, Inc. Improved methods for inducing tissue regeneration and senolysis in mammalian cells
CA3135200A1 (en) * 2019-03-28 2020-10-01 Agex Therapeutics, Inc. Induced tissue regeneration using extracellular vesicles
US20220316013A1 (en) * 2019-08-23 2022-10-06 Agex Therapeutics, Inc. Differentially-methylated regions of the genome useful as markers of embryo-adult transitions
US20240066070A1 (en) * 2021-01-12 2024-02-29 Agex Therapeutics, Inc. Methods for the ex vivo induction of tissue regeneration in microbiopsies
WO2023064572A2 (en) * 2021-10-15 2023-04-20 Agex Therapeutics, Inc. Methods for the temporal regulation of reprogramming factors in mammalian cells
WO2023114274A1 (en) * 2021-12-14 2023-06-22 Agex Therapeutics, Inc. Improved methods for inducing the maturation of mammalian cells
WO2025155772A1 (en) * 2024-01-19 2025-07-24 Gene Company (Pty)Ltd. Alpha-1 anti-trypsin upregulating polynucleotides and method of use and treatment thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014197421A1 (en) * 2013-06-05 2014-12-11 Biotime, Inc. Compositions and methods for induced tissue regeneration in mammalian species
CN105435244A (zh) * 2015-12-02 2016-03-30 重庆高圣生物医药有限责任公司 Lin28a基因过表达腺相关病毒在促进创伤修复中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067245A2 (en) * 2007-11-20 2009-05-28 University Of Florida Research Foundation, Inc. Compositions and methods for tissue repair
US20130202564A1 (en) * 2010-04-09 2013-08-08 University Of Southern California Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration
ES2590461T3 (es) * 2010-07-02 2016-11-22 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii La transcriptasa inversa de la telomerasa como protección frente al envejecimiento
AU2017278931B2 (en) * 2016-06-07 2023-06-29 Agex Therapeutics, Inc. Improved methods for detecting and modulating the embryonic-fetal transition in mammalian species

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014197421A1 (en) * 2013-06-05 2014-12-11 Biotime, Inc. Compositions and methods for induced tissue regeneration in mammalian species
CN105435244A (zh) * 2015-12-02 2016-03-30 重庆高圣生物医药有限责任公司 Lin28a基因过表达腺相关病毒在促进创伤修复中的应用

Also Published As

Publication number Publication date
JP2023017861A (ja) 2023-02-07
AU2023203808A1 (en) 2023-07-13
US20190175691A1 (en) 2019-06-13
EP3463391A1 (en) 2019-04-10
AU2017278931A1 (en) 2018-12-20
JP2019517538A (ja) 2019-06-24
US20220088137A1 (en) 2022-03-24
EP3463391A4 (en) 2020-01-22
CA3026874A1 (en) 2017-12-14
US20220088138A1 (en) 2022-03-24
US20220160833A1 (en) 2022-05-26
WO2017214342A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
US20220088138A1 (en) Methods for detecting and modulating the embryonic-fetal transition in mammalian species
US12492400B2 (en) Compositions and methods for induced tissue regeneration in mammalian species
EP3784232B1 (en) Improved methods for inducing tissue regeneration and senolysis in mammalian cells
US20240066070A1 (en) Methods for the ex vivo induction of tissue regeneration in microbiopsies
US20240398987A1 (en) Methods for the temporal regulation of reprogramming factors in mammalian cells
US20240350553A1 (en) Methods for modulating the regenerative phenotype in mammalian cells

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: AGEX THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): BIOTIME, INC.

FGA Letters patent sealed or granted (standard patent)